Exchange: NASDAQ·Updated 05:43 PM EDT
News
all
press releases
HALO Stock Rises 36% in a Month: Here's What You Should Know
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
Zacks
More News
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
Zacks
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co raised the price target for argenx SE - ADR (NASDAQ: ARGX) from $940 to $1,202. Goldman...
Benzinga
These Analysts Boost Their Forecasts On Argenx
Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.read more...
Benzinga
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of $60.86 billion.read more...
Benzinga
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint...
Business Wire
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will...
Business Wire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of $54.18 billion.read more...
Benzinga
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Zacks
What Makes Argenx (ARGX) a New Buy Stock
Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.